NCT03738904

Prospective Randomized Controlled Trial of an Enhanced Recovery Protocol for Anorectal Surgery

Cedars-Sinai Medical Center·Phase 4·ClinicalTrials.gov·combination productRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Anorectal Disorder
Drug/Device/Intervention
ERAS
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
Cedars-Sinai Medical Center
Location
Los Angeles, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Oct 26, 2018
End date
Dec 31, 2022
Enrollment
88 participants
Primary outcome

Total narcotic use postoperatively in oral morphine equivalents

Summary

The purpose of the study is to evaluate whether being randomized to an aggressive
 postoperative non-narcotic pain regimen that treats pain from multiple different pathways may
 decrease postoperative pain levels, decrease constipation, and decrease the dependency on
 opioid medications after anorectal surgery versus the standard of care for managing pain.
 This use of a more aggressive pain regimen is considered an enhanced recovery after surgery
 (ERAS) protocol because it is theorized to improve or enhance postoperative recovery by
 both decreasing the use of narcotics and their detrimental effects as well as increasing the
 benefit of using additional non-narcotic pain medication.

ICD-10 classifications
AnorexiaAnorexia nervosaAnorectal abscessAtypical anorexia nervosaAnorectal fistula
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03738904
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03738904 through Pure Global AI's free database. This Phase 4 trial is sponsored by Cedars-Sinai Medical Center and is currently Recruiting. The study focuses on Anorectal Disorder. Target enrollment is 88 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.